829 Shares in Medtronic PLC $MDT Bought by Traub Capital Management LLC

Traub Capital Management LLC purchased a new stake in Medtronic PLC (NYSE:MDT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 829 shares of the medical technology company’s stock, valued at approximately $72,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. 1248 Management LLC bought a new position in shares of Medtronic in the 1st quarter valued at about $26,000. Twin Tree Management LP acquired a new position in Medtronic during the first quarter valued at approximately $29,000. Activest Wealth Management boosted its position in Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares during the last quarter. Investment Management Corp VA ADV grew its stake in Medtronic by 144.2% in the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 238 shares in the last quarter. Finally, GFG Capital LLC acquired a new position in shares of Medtronic during the 2nd quarter worth approximately $36,000. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on MDT. Daiwa Capital Markets increased their price objective on Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a report on Friday, September 12th. Robert W. Baird upped their price target on shares of Medtronic from $103.00 to $109.00 and gave the stock a “neutral” rating in a research report on Wednesday. Argus increased their price target on shares of Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, August 26th. Sanford C. Bernstein restated an “outperform” rating and set a $98.00 price objective on shares of Medtronic in a research note on Friday, October 31st. Finally, Leerink Partners set a $120.00 target price on shares of Medtronic and gave the company an “outperform” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $108.50.

Insider Buying and Selling

In other news, Director William R. Jellison purchased 2,500 shares of Medtronic stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. This trade represents a 100.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.26% of the company’s stock.

Medtronic Price Performance

NYSE:MDT opened at $100.12 on Thursday. The company has a market cap of $128.42 billion, a P/E ratio of 27.58, a P/E/G ratio of 2.42 and a beta of 0.77. The firm’s fifty day moving average price is $94.80 and its two-hundred day moving average price is $90.70. Medtronic PLC has a one year low of $79.29 and a one year high of $102.59. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the company posted $1.26 EPS. Medtronic’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.